EMJ Dermatology 7 [Suppl 10] . 2019

In this issue

IL-23 came under the spotlight during this year’s European Academy of Dermatology and Venereology (EADV) Congress in Madrid, Spain, as the subject of a symposium co-chaired by Profs Reich and Warren, and with the latest data from the guselkumab clinical trial programme, reviewed in two separate articles in the latest addition to EMJ Dermatology.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.